Cointime

Veralox Therapeutics

company

About

Veralox Therapeutics develops small molecule therapeutics that treat the underlying pathologies of thrombosis and type one diabetes.

  • 1 - 10

Highlights

Total Funding Amount
$22M
Funding Rounds
2
Investors
3

Details

Last Funding Type
Seed
Last Funding Money Raised
$5.40M
Industries
Biotechnology,Medical,Pharmaceutical,Therapeutics
Founded date
Jan 1, 2017
Number Of Employee
1 - 10
Operating Status
Active

Veralox Therapeutics develops small molecule therapeutics that treat the underlying pathologies of thrombosis and type one diabetes. Based on an understanding of the molecular mechanisms of these diseases, these efforts will lead to new treatment paradigms and better outcomes for patients.

Funding Rounds

Number of Funding Rounds
Total Funding Amount
2
$22M
Veralox Therapeutics has raised a total of $22M in funding over 2 rounds. Their latest funding was raised on Jun 16, 2021 from a Series A round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
Jun 16, 2021 Series A $16.60M 1 — — Detail
Sep 5, 2019 Seed $5.40M 3 Sanofi
VTC Seed Fund 		— Detail

Investors

Number of Lead Investors
Number of Investors
2
3
Veralox Therapeutics is funded by 3 investors. Sanofi and VTC Seed Fund are the most recent investors.
Investor Name Lead Investor Funding Round
Sanofi Yes Seed
VTC Seed Fund Yes Seed
TEDCO — Series A
Cointime
Содержание
компания